Effect of MD1003 (High-Dose Biotin) in spinal progressive multiple sclerosis (MS-SPI): EDSS sub-scores

被引：0
|
作者：
Papeix, C. [1 ]
Lebrun-Frenay, C. [2 ]
Defer, G. [3 ]
Labauge, P. [4 ]
Ruiz, M. [5 ,6 ,7 ]
Simon, O. [7 ]
Tourbah, A. [8 ]
机构：
[1] GH Pitie Salpetriere, Dept Neurol, Paris, France
[2] Univ Cote Azur, CHU Pasteur Neurol 2, Nice, France
[3] CHU Caen, Serv Neurol, Caen, France
[4] CHU Montpellier, Dept Neurol, Montpellier, France
[5] UPMC Univ Paris 06, Sorbonne Univ, Paris, France
[6] Hop La Pitie Salpetriere, AP HP, Dept Neurol, Paris, France
[7] MedDay Pharmaceut, Paris, France
[8] Hop Maison Blanche, Dept Neurol, Reims, France
来源：
MULTIPLE SCLEROSIS JOURNAL | 2017年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EP1780
引用
收藏
页码：938 / 939
页数：2
相关论文
共 50 条
  • [21] Long term effect of MD1003 (high dose pharmaceutical grade biotin) in a cohort of patients with progressive non-active multiple sclerosis
    Donze, C.
    Guyot, M. A.
    Kwiatkowski, A.
    Hautecoeur, P.
    Massot, C.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 385 - 385
  • [22] MD1003 (High-Dose Biotin) for the treatment of progressive multiple sclerosis: baseline data and results from a cohort of patients included in a early access program
    Brassat, D.
    Hautecoeur, P.
    Durand-Dubief, F.
    Castelnovo, G.
    Derache, N.
    Bourre, B.
    Le Page, E.
    Donze, C.
    Audoin, B.
    Ouallet, J-C.
    Collongues, N.
    Simon, O.
    Brion, G.
    Vermersch, P.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 936 - 937
  • [23] Treatment of progressive MS with MD1003 (high dose pharmaceutical grade biotin): real-world evidence
    Ciron, J.
    Pignolet, B.
    Bucciarelli, F.
    Biotti, D.
    Lerebours, F.
    Dorcet, G.
    Rabadeux, C.
    Freitas, N.
    Bonneville, F.
    Brassat, D.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 693 - 693
  • [24] Real-world effectiveness of MD1003 (high dose pharmaceutical grade biotin) in patients with progressive MS
    Faure, J.
    Jauffret, J.
    Carreau, C.
    Legrain, P.
    Castex, C.
    Tourbah, A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 281 - 282
  • [25] Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial
    Cree, Bruce A. C.
    Cutter, Gary
    Wolinsky, Jerry S.
    Freedman, Mark S.
    Comi, Giancarlo
    Giovannoni, Gavin
    Hartung, Hans-Peter
    Arnold, Douglas
    Kuhle, Jens
    Block, Valerie
    Munschauer, Frederick E.
    Sedel, Frederic
    Lublin, Fred D.
    [J]. LANCET NEUROLOGY, 2020, 19 (12): : 988 - 997
  • [26] High dose pharmaceutical grade biotin (MD1003) protects axons in a TMEV-induced mouse model of progressive multiple sclerosis
    Warrington, A.
    Perdomini, M.
    Bernard, D.
    Rodriguez, M.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 532 - 533
  • [27] Immunomodulation associated with clinical and MRI worsening in patients with progressive MS treated with MD1003 (high dose pharmaceutical grade biotin)
    Pignolet, B.
    Ciron, J.
    Bucciarelli, F.
    Scandella, L.
    Biotti, D.
    Lerebours, F.
    Dorcet, G.
    Rabadeux, C.
    Freitas, N.
    Bonneville, F.
    Brassat, D.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 467 - 468
  • [28] Beneficial Effects of High-dose Biotin (MD1003) in Models of X-linked adrenoleukodystrophy
    Fourcade, Stephane
    Parameswaran, Janani
    Goicoechea, Leire
    Launay, Nathalie
    Ruiz, Montserrat
    Sedel, Frederic
    Pujol, Aurora
    [J]. NEUROLOGY, 2019, 92 (15)
  • [29] Beneficial effects of high-dose biotin (MD1003) in models of X-linked adrenoleukodystrophy
    Fourcade, S.
    Parameswaran, J.
    Goicoechea, L.
    Launay, N.
    Ruiz, M.
    Sedel, F.
    Pujol, A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 521 - 522
  • [30] Effect of MD1003 (high dose pharmaceutical grade biotin) for the treatment of progressive MS: 48-month follow-up data
    De Seze, J.
    Edan, G.
    Moreau, T.
    Brochet, B.
    Sedel, F.
    Tourbah, A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 287 - 288
12345